Clinical Trials Browser

Terminated × Urethral Neoplasms × Clear all

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT02122172 2025-04-25

Afatinib in Advanced Refractory Urothelial Cancer

Phase 2 Terminated

32 enrolled 14 charts

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT03397394 2023-06-09

ATLAS

Phase 2 Terminated

97 enrolled 12 charts

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT02612194 2022-11-03

LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer

Phase 2 Terminated

8 enrolled 16 charts

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT01353222 2017-05-25

DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

Phase 2 Terminated

142 enrolled 13 charts

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Ureteral Neoplasms, Urethral Neoplasms

NCT00022633 2016-08-11

S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract

Phase 2 Terminated

65 enrolled 14 charts

Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00112905 2014-05-30

Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium

Phase 2 Terminated

27 enrolled 8 charts

Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00004856 2013-05-03

Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium

Phase 2 Terminated

40 enrolled

Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00087295 2012-11-02

S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium

Phase 2 Terminated

6 enrolled

Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

Clinical Trials

EV-103

Afatinib in Advanced Refractory Urothelial Cancer

ATLAS

LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer

DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract

Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium

Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium

S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium